
Steris
STE · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $25,7 bn
- Div. yield
- 1,0%
- Year to date
- +4,3%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
5 ✓ · 2 — · 1 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 31,9 | 48,7 | 25,1 |
| Forward P/E | 23,1 | — | 16,2 |
| PEG | 1,6 | — | 2,2 |
| P/S | 4,3 | 4,1 | 2,2 |
| EV/EBITDA | 16,6 | 18,0 | 17,3 |
| P/FCF | 27,7 | — | 19,5 |
| P/B | 3,6 | 3,4 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 13 analysts
- Buy
- 9
- Hold
- 4
- Sell
- 0
Beat the EPS forecast in 2 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q2 2027 | 2,70 | 2,94 | Up +8,8% |
| Q1 2027 | 2,53 | 2,59 | Up +2,5% |
| Q4 2026 | 2,88 | 2,83 | Down −1,6% |
| Q3 2026 | 2,56 | 2,53 | Down −1,1% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,59 bn | 1,49 bn | 1,59 bn | 1,50 bn | 1,46 bn | 1,39 bn | 1,48 bn | 1,37 bn | 1,33 bn | 1,28 bn | 1,42 bn | 1,40 bn |
| EPS | — | — | 2,24 | 1,96 | 1,94 | 1,79 | 1,47 | 1,75 | 1,51 | 1,46 | −0,01 | 1,42 |
| Margin | 13,5% | 13,4% | 13,9% | 12,9% | 13,1% | 12,8% | 9,8% | 12,7% | 11,3% | 11,4% | −0,1% | 10,1% |
| FCF | 213 m | 280 m | 245 m | 200 m | 201 m | 326 m | 190 m | 244 m | 149 m | 196 m | 163 m | 172 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $8,60 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| burton karen l11 Nov 2026 · sale | $1,50 m | 5 880 | $255,62 |
| sohi mohsen10 Nov 2026 · sale | $422 744 | 1 665 | $253,90 |
| sohi mohsen10 Nov 2026 · sale | $816 264 | 3 228 | $252,87 |
| sohi mohsen12 Aug 2026 · sale | $956 795 | 4 058 | $235,78 |
| zangerle john adam15 Jun 2026 · sale | $296 968 | 1 419 | $209,28 |
| carestio daniel a5 Jun 2026 · sale | $291 288 | 1 374 | $212,00 |
| carestio daniel a4 Jun 2026 · sale | $655 511 | 3 054 | $214,64 |
| breeden richard c2 Jun 2026 · sale | $310 284 | 1 481 | $209,51 |
| feldmann cynthia l5 Mar 2026 · sale | $734 877 | 3 098 | $237,21 |
| madsen julia21 Nov 2025 · sale | $559 632 | 2 136 | $262,00 |
| madsen julia21 Nov 2025 · sale | $752 464 | 2 872 | $262,00 |
| tamaro renato18 Nov 2025 · sale | $386 640 | 1 500 | $257,76 |
| tamaro renato18 Nov 2025 · sale | $54 702 | 212 | $258,03 |
| tamaro renato18 Nov 2025 · sale | $855 697 | 3 324 | $257,43 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- IE
- IPO date
- 3 Nov 2015
- Website
- www.steris.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
DGXQuest Diagnostics | $262,21 | 61★★★★★★★★would watch | 25,5 | +9,1% | 9,5% |
LHLabcorp | $372,46 | 56★★★★★★★★would watch | 30,0 | +6,0% | 6,9% |
DXCMDexcom | $81,61 | 89★★★★★★★★★★would consider | 31,4 | +13,0% | 19,4% |
RMDResMed | $238,19 | 83★★★★★★★★★would consider | 21,3 | +9,0% | 27,8% |
CNCCentene Corporation | $74,77 | 72★★★★★★★★★would consider | 24,2 | +9,7% | 0,7% |
Ratio — a score by our methodology, not an investment recommendation.




